Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Adaptimmune Therapeutics plc (NASDAQ: ADAP) and TCR² Therapeutics Inc. is fair to Adaptimmune shareholders. Under the terms of the agreement, TCR² stockholders will receive 1.5117 Adaptimmune ADS for each TCR² share. Following the closing of the transaction, Adaptimmune shareholders will own approximately 75% of the combined company.

Halper Sadeh encourages Adaptimmune shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

The investigation concerns whether Adaptimmune and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Adaptimmune shareholders; and (2) disclose all material information necessary for Adaptimmune shareholders to adequately assess and value the merger consideration. On behalf of Adaptimmune shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh encourages Adaptimmune shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005530/en/